Journal of Clinical Oncology, Vol 16, 48-55, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial

PJ Stiff, S Dahlberg, SJ Forman, AR McCall, SJ Horning, AP Nademanee, KG Blume, M LeBlanc and RI Fisher
Loyola University Stritch School of Medicine, Maywood, IL, USA.

PURPOSE: To determine the toxicity and prognosis of patients with relapsed and refractory diffuse aggressive non-Hodgkin's lymphoma (NHL) who underwent an autologous bone marrow transplant (ABMT) using augmented preparative regimens, treated in a major cooperative group setting, and to examine prognostic factors for outcome. PATIENTS AND METHODS: Ninety-four patients with either chemosensitive (50 patients) or chemoresistant (44 patients) relapse, including 22 who failed induction chemotherapy, were treated with high-dose cyclophosphamide and etoposide with total-body irradiation (TBI) (67 patients) or an augmented carmustine (BCNU), cyclophosphamide, and etoposide (BCV) preparative regimen (27 patients) and an ABMT at 16 Southwest Oncology Group (SWOG) transplant centers. All relapsing patients were required to undergo a minimum of two courses of salvage therapy to determine chemosensitivity before transplant. Overall (OS) and progression-free survival (PFS) were determined and a Cox regression model was used to assess potential prognostic variables. RESULTS: Of the 94 eligible patients, there were 10 (10.6%) deaths before day 50 posttransplant because of infection (six deaths), hemorrhagic alveolitis (three deaths), or bleeding (one death). The median 3-year PFS and OS for the entire group was 33% and 44%. For those with chemosensitive disease the PFS and OS were 42% and 55%, whereas for those with chemoresistant disease the PFS and OS were 22% and 29%. The PFS and OS for those failing induction chemotherapy were 27% and 32%. The relapse rates within the first 3 years for the chemosensitive relapse, chemoresistant, and induction failure groups were 61%, 40%, and 59%, respectively. For both PFS and OS, only disease status at transplant was a significant factor in the multivariate Cox model. CONCLUSION: These results single institutional pilot trials exploring augmented preparative regimens. Patients undergoing transplantation for resistant disease, particularly those failing induction chemotherapy, appear to have an improved prognosis as compared with reports using standard preparative regimens. Therapies other than manipulation of standard preparative regimens appear to be required to decrease relapses following autotransplantation.

This article has been cited by other articles:

				J. A. Thompson, R. I. Fisher, M. LeBlanc, S. J. Forman, O. W. Press, J. M. Unger, A. P. Nademanee, P. J. Stiff, S. H. Petersdorf, and A. Fefer Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438) Blood, April 15, 2008; 111(8): 4048 - 4054. [Abstract] [Full Text] [PDF]

				B. S. Hoppe, C. H. Moskowitz, D. A. Filippa, C. S. Moskowitz, T. Kewalramani, A. D. Zelenetz, and J. Yahalom Involved-Field Radiotherapy Before High-Dose Therapy and Autologous Stem-Cell Rescue in Diffuse Large-Cell Lymphoma: Long-Term Disease Control and Toxicity J. Clin. Oncol., April 10, 2008; 26(11): 1858 - 1864. [Abstract] [Full Text] [PDF]

				A. K. Gopal, J. G. Rajendran, T. A. Gooley, J. M. Pagel, D. R. Fisher, S. H. Petersdorf, D. G. Maloney, J. F. Eary, F. R. Appelbaum, and O. W. Press High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults >= 60 Years Old With Relapsed or Refractory B-Cell Lymphoma J. Clin. Oncol., April 10, 2007; 25(11): 1396 - 1402. [Abstract] [Full Text] [PDF]

				P. J. Stiff, C. Emmanouilides, W. I. Bensinger, T. Gentile, B. Blazar, T. C. Shea, J. Lu, J. Isitt, A. Cesano, and R. Spielberger Palifermin Reduces Patient-Reported Mouth and Throat Soreness and Improves Patient Functioning in the Hematopoietic Stem-Cell Transplantation Setting J. Clin. Oncol., November 20, 2006; 24(33): 5186 - 5193. [Abstract] [Full Text] [PDF]

				A. Nademanee, S. Forman, A. Molina, H. Fung, D. Smith, A. Dagis, C. Kwok, D. Yamauchi, A.-L. Anderson, P. Falk, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma Blood, October 15, 2005; 106(8): 2896 - 2902. [Abstract] [Full Text] [PDF]

				J. M. Vose, P. J. Bierman, C. Enke, J. Hankins, G. Bociek, J. C. Lynch, and J. O. Armitage Phase I Trial of Iodine-131 Tositumomab With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Relapsed Non-Hodgkin's Lymphoma J. Clin. Oncol., January 20, 2005; 23(3): 461 - 467. [Abstract] [Full Text] [PDF]

				R. Spielberger, P. Stiff, W. Bensinger, T. Gentile, D. Weisdorf, T. Kewalramani, T. Shea, S. Yanovich, K. Hansen, S. Noga, et al. Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers N. Engl. J. Med., December 16, 2004; 351(25): 2590 - 2598. [Abstract] [Full Text] [PDF]

				C. O. Freytes, F. R. Loberiza, J. D. Rizzo, A. Bashey, C. N. Bredeson, M. S. Cairo, R. P. Gale, M. M. Horowitz, T. R. Klumpp, R. Martino, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry Blood, December 1, 2004; 104(12): 3797 - 3803. [Abstract] [Full Text] [PDF]

				J. Rodriguez, M. D. Caballero, A. Gutierrez, C. Solano, R. Arranz, J. J. Lahuerta, J. Sierra, M. Gandarillas, J. A. Perez-Simon, J. Zuazu, et al. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience Ann. Onc., October 1, 2004; 15(10): 1504 - 1509. [Abstract] [Full Text] [PDF]

				M. Jermann, L. M. Jost, Ch. Taverna, E. Jacky, H. P. Honegger, D. C. Betticher, F. Egli, Th. Kroner, and R. A. Stahel Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study Ann. Onc., March 1, 2004; 15(3): 511 - 516. [Abstract] [Full Text] [PDF]

				R. I. Fisher Autologous Stem-Cell Transplantation as a Component of Initial Treatment for Poor-Risk Patients With Aggressive Non-Hodgkin's Lymphoma: Resolved Issues Versus Remaining Opportunity J. Clin. Oncol., November 15, 2002; 20(22): 4411 - 4412. [Full Text] [PDF]

				J. M. Vose, G. Sharp, W. C. Chan, C. Nichols, K. Loh, D. Inwards, R. Rifkin, P. J. Bierman, J. C. Lynch, D. D. Weisenburger, et al. Autologous Transplantation for Aggressive Non-Hodgkin's Lymphoma: Results of a Randomized Trial Evaluating Graft Source and Minimal Residual Disease J. Clin. Oncol., May 1, 2002; 20(9): 2344 - 2352. [Abstract] [Full Text] [PDF]

				J. M. Vose, M.-J. Zhang, P. A. Rowlings, H. M. Lazarus, B. J. Bolwell, C. O. Freytes, S. Pavlovsky, A. Keating, B. Yanes, K. van Besien, et al. Autologous Transplantation for Diffuse Aggressive Non-Hodgkin's Lymphoma in Patients Never Achieving Remission: A Report from the Autologous Blood and Marrow Transplant Registry J. Clin. Oncol., January 15, 2001; 19(2): 406 - 413. [Abstract] [Full Text] [PDF]

				R. I. Fisher Autologous Bone Marrow Transplantation for Aggressive Non-Hodgkin's Lymphoma: Lessons Learned and Challenges Remaining J Natl Cancer Inst, January 3, 2001; 93(1): 4 - 5. [Full Text] [PDF]

				T. Kewalramani, A. D. Zelenetz, E. E. Hedrick, G. B. Donnelly, S. Hunte, A. C. Priovolos, J. Qin, N. C. Lyons, J. Yahalom, S. D. Nimer, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis Blood, October 1, 2000; 96(7): 2399 - 2404. [Abstract] [Full Text] [PDF]

				C. Aristei and A. Tabilio Total-Body Irradiation in the Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoproliferative Diseases Oncologist, October 1, 1999; 4(5): 386 - 397. [Abstract] [Full Text]